X4 Pharmaceuticals Inc. Q1 2023 Earnings Call

Putting all of this infection information in just a couple of weeks.

Perfect. Thank you so much.

The next question comes from RK with H C Wainwright.

Please go ahead.

Thank you good morning, Paula and Adam This is RK from H C Wainwright.

I think if I do my job right on on May 16th and 20, plus I Shouldnt call Oliver Wyman Maverix before.

But at the same time, you're putting five kols together on the 16th.

So should we expect.

These folks to be talking about.

Additional neutropenia conditions, where maverix football it could be used.

And.

Also this help you to initiate conversations regarding.

The subtypes of S. M. In defense, you know SCM gets generated by but do the videos causes.

Some color around that come up in this conversation so for us to think about a potential expansion indication expansions or maverick support.

Yeah, I think so much great question I think the kols on the call our breath of Kols in the U S and Europe and then across.

Hematology immunology and in some cases, rheumatology, which is somewhere.

They're managed so we felt we wanted to have that nice universe of experiences commenting not only on <unk>.

Data and win but some of them certainly have relevance in treating a larger number of chronic neutropenia patient. So for those for those folks that have that experience they will be able to bring in their experiences into the conversation and we have a few of them live on the events at the end said there'll be able to speak.

From their perspective, and certainly we'll look forward to the Q&A around that topic around future indications.

Thank you. Thank you looking forward to those three months.

Okay. Thank you so much okay.

The next question comes from Kristen <unk> with Cantor Fitzgerald.

Please go ahead.

Good morning. This is Rick on for Kristen. Thank you for taking our questions to kind of set the stage ahead of the Cif conference and when could you talk a little bit about the setting the audience, you're expecting it's Cif and how getting in front of this audience could help inform what you understand could be the prescriber community that you could be focusing on in women.

Sure. So I think at Cas's, primarily immunologists.

Mark has a team.

Participating in this conference I'll turn it over to him to Bryan additional color Marc Thanks, Paul Hi, Rick.

Yes, we're looking forward to.

Being a Cif where a lot of our customers are planning to be we have a number of.

Meeting setup with key customers and we will have.

Our company booths, there as well, which is focused on raising disease awareness of win so.

We think it's going to be very valuable conference for US is the excitement builds around that around the release of that phase III data.

Great and maybe just one more on the CN poster presentation, you announced for <unk> could you also kind of set the stage here, what we could expect potentially from this real world patient data that you talked about should we be expecting mostly patients managed on C. G. CSF and do you plan on <unk>.

Into any information on genetic background for the patients in this study.

Yeah, So it's a.

The higher level set even that we don't get into obviously genetics are sometimes not even captured in electronic medical records.

So it is a higher level study on the populations that are diagnosed with different types of chronic neutropenia, there's different ICD 10 code and then theres a different ability to drill down on their clinical history in terms of their severe infection event.

Posted really connect those dots are is that real world evidence connecting degrees of neutropenia with severity around.

Morbidity and potentially in some cases of mortality.

I look forward to sharing our poster and certainly had a follow up question as the community data.

Excellent. Thank you very much.

This concludes the question answer session I would now like to turn the conference back over to Dr. Reagan for any closing remarks.

Thank you so much we appreciate everyone attending today and we certainly look forward to having everyone and hopefully your interest on our big may 16th events have a great rest of your day take care.

This concludes today's conference call you may disconnect your lines.

Thank you for participating and have a pleasant day.

Okay.

Yes.

Okay.

Okay.

Okay.

Okay.

Yes.

Okay.

Yes.

Yeah.